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Abstract
Limited data on relative ﬁtness and virulence of antimicrobial-
resistant Acinetobacter baumannii are known. We aimed to study
the virulence and ﬁtness cost of ciproﬂoxacin-resistance in
A. baumannii (CipR) compared with the susceptible parental
wild-type strain (CipS). Human lung epithelial cells were infected
with CipS and CipR for 24 h. Competition ﬁtness was moni-
tored in vitro and in vivo in a murine peritoneal sepsis model. We
showed that CipR induced less cell death than CipS and CipR
growth was slow when in competition with CipS. Altogether,
acquisition of ciproﬂoxacin resistance confers a biological ﬁtness
cost and reduces virulence in A. baumannii.
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Antibiotic resistance emergence in a bacterial population is
produced by several factors, of which rate of mutation to
resistance and ﬁtness cost of mutants have been considered
critical [1]. A consistent ﬁtness cost may appear when chro-
mosomal mutations cause structural modiﬁcations in the cel-
lular target of a drug and when efﬂux pumps are
overexpressed [2,3]. In the case of ﬂuoroquinolones, resis-
tance is mainly acquired by increasing efﬂux pump and DNA
gyrase and topoisomerase mutations, [4]. This resistance has
been widely shown to slow the growth and the virulence of
Escherichia coli and Salmonella enterica [5,6]. Contradictory
data are observed in E. coli resistant to ciproﬂoxacin due to
parC and gyrA mutations, which did not decrease the growth
rate in vitro and in vivo [7]. In the same line, the relative
growth rate of a ciproﬂoxacin-resistant S. pneumoniae strain
due to parC mutation was identical to its susceptible isogenic
parental strain [8].
Acinetobacter baumannii has become one of the leading
nosocomial pathogens worldwide. Resistance to ﬂuoroqui-
nolones has increased in A. baumannii [9]. In the UK, 49.1%
of 226 A. baumannii isolates were resistant to ciproﬂoxacin
and 68.5% of these resistant isolates had an MIC of ‡32 mg/
L and mutations in gyrA and parC [10]. Fitness costs in A. bau-
mannii remain largely unknown. A. baumannii and Acinetobac-
ter sp. resistant to colistin and rifampin impaired ﬁtness and
increased duplication times compared with the parental
strain [11,12]. Besides these works, there are no reports on
the ﬁtness cost for A. baumannii resistant to ﬂuoroquinol-
ones.
Expanded details of all materials and methods are given in
the Supplemental Data.
Bacterial strains: 77wt is a clinical isolate susceptible to
ciproﬂoxacin (CipS) [13]. 77R is a ciproﬂoxacin-resistant
strain (CipR) obtained by exposing CipS to repeated in vitro
subinhibitory concentrations of ciproﬂoxacin.
In vitro susceptibility testing: Ciproﬂoxacin MICs for CipS
and CipR were determined by microdilution in the presence
or absence of Phe-Arg-b-naphthylamide [14] and reserpine
[13].
Bioﬁlm: Bioﬁlm formation assay was performed as
described previously [15].
Cellular viability: A549 cells were infected with CipS and
CipR. A. baumannii cytotoxicity was assessed using the MTT
assay [16], the LIVE/DEAD and the cytotoxicity detection
kits.
Sepsis peritoneal infection model: A peritoneal sepsis model
was used [12]. Mice were inoculated with different bacterial
incoula of CipS and CipR.
Competition experiments: The in vitro and in vivo competition
index (CI) was determined from growth cultures of CipS,
CipR and a mixed CipS and CipR.
Ciproﬂoxacin MICs against CipS and CipR were 1 and
32 mg/L, respectively. CipR incubation with efﬂux pump
inhibitors PAbN and reserpine showed a decreased
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ciproﬂoxacin MIC four and six-fold, respectively (Table S1).
No additional mutations in gyrA and parC between the CipS
and the CipR were observed (data not shown). These results
imply that ciproﬂoxacin resistance in CipR is due at least to
the overexpression of an active efﬂux pump. Furthermore,
we showed that the CipR produced less bioﬁlm than the
CipS (Fig. S1).
Cell survival assessment by MTT assay showed that incu-
bation of A549 cells with CipS reduced cell viability to
66.23 ± 4.01%. In contrast, CipR induced a little reduction
in cell viability to 86.53 ± 2.44%. As a positive control,
incubation of A549 cells with staurosporine reduced cell
viability to 33.12 ± 10.06% (Fig. 1a). A. baumannii cytotoxic-
ity was also assessed using a two-colour ﬂuorescence cell
viability assay. We showed that CipS induced more cell
death, as indicated by red ﬂuorescence, than CipR (Fig. 1b).
Additionaly, lower levels of LDH liberation, a necrotic cell
sign, were detected in infected A549 cells with CipR
(5.98 ± 1.81%) than with CipS (48.38 ± 3.5%) (Fig. 1c).
These results showed that acquisition of ciproﬂoxacin resis-
tance by an active efﬂux pump impaired cytotoxicity
induced by A. baumannii.
We detect a signiﬁcant difference in mortality caused by
CipS and CipR, independently of the size of inoculums (Table
S2). Kaplan–Meier analysis revealed differences between ani-
mal groups receiving the same inoculum (p = 0.002, p = 0.07
and p = 0.04 for approximately 8.3, 7.3 and 6.3 log CFU/mL,
respectively) (Fig. S2). These results indicate that acquisition
of ciproﬂoxacin resistance by an active efﬂux pump interferes
with infective capacity and mortality caused by A. baumannii
in vivo.
An in vitro competition experiment showed statistical dif-
ferences between CipS and CipR (CI = 0.02; p = 0.04).
Growth rates of CipS and CipR cultures were similar, with
the exception of the experiments in which both strains were
grown together, showing a lower growth of 1.7 log of the
CipR (Fig. 2a). These data were conﬁrmed in vivo. CFUs in
spleens from animals infected with CipS or CipR differed by
2.02 log at 24 h, whereas the difference was 2.82 log in the




FIG. 1. Cell death induced by Acinetobacter baumannii. A549 cells
were infected with 108 CFU/mL of A. baumannii CipS and CipR for
24 h. A. baumannii cytotoxicity was assessed by monitoring the mito-
chondrial reduction activity using the MTT assay (a), illustrated with
representative microscopic ﬁelds of the two-colour ﬂuorescence cell
viability assay (LIVE/DEAD Kit) (b), and determined by following
LDH release using the cytotoxicity detection assay (c). The positive
control was 10 mg/L staurosporine (Str). Representative results of
three independent experiments are shown and data are
the means ± SD. p < 0.05: *between A549 cells and inoculated
groups,  between inoculated groups.
(a)
(b)
FIG. 2. In vitro and in vivo competition growth of A. baumannii. CipS,
CipR and mixed inoculum were grown in vitro (a) and in vivo after i.p.
inoculation with 8.3 Log CFU/mL in mice (b) for 24 h.
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data demonstrate that acquisition of ciproﬂoxacin resistance
by an active efﬂux pump affects the ﬁtness of A. baumannii in
vitro and in vivo.
The data presented in our study revealed overexpression
of efﬂux pumps in the CipR strain with ciproﬂoxacin MIC of
32 mg/L and absence of mutations in gyrA and parC. In
another study, two clinical A. baumannii isolates with cipro-
ﬂoxacin MICs of 8 and >32 mg/L presented a mutation in
parC but not in gyrA and an overexpression of an efﬂux
pump adeB [17]. Decreased growth in ﬂuoroquinolone resis-
tance isolates could result from inopportune efﬂux of nutri-
ents and metabolic intermediates by overexpressed MDR
efﬂux pumps [18]. However, evidence to support this
hypothesis is currently lacking.
Our results have also demonstrated that the CipR strain
was less virulent in vitro and in vivo. Previously, we reported
that CipR A. baumannii induced less cell death than CipS
strains [15]. Overexpression of efﬂux pumps by P. aeruginosa
was associated with reduction of the gene expression that
encodes the type III secretion system and was proposed to
cause a concomitant lack of ﬁtness [19]. Gene expression
associated with Acinetobacter sp. virulence was autoinduced
by quorum-sensing signal molecules [20]. As efﬂux pumps
have been shown to expel quorum-sensing signals in P. aeru-
ginosa [21], we suggest that altered quorum-sensing signal
homeostasis, resulting from increased efﬂux pump activities,
may have contributed to the decreased virulence of the CipR
strain observed in our study. More studies are needed to
conﬁrm the relationship between efﬂux pumps and speciﬁc
genes involved in A. baumannii virulence.
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Figure S1. One-day bioﬁlm formation. Bioﬁlm formation
of Acinetobacter baumannii CipS and CipR is shown. Repre-
sentative results of three independent experiments are
shown and data are the means ± SD. p <0.05: *between
MHB and inoculated groups, between inoculated groups.
Figure S2. Mortality curves. Mice were infected with
three different inocula (8.3, 7.3, and 6.3 CFU/mL) of Acineto-
bacter baumannii 77 wt strain (black lines) and its ciproﬂoxa-
cin resistant mutant 77R strain (gray lines). Mortality curves
are analysed by Kaplan-Meier survival analysis.
Table S1. In vitro activity of ciproﬂoxacin against Acineto-
bacter baumannii strains in the presence and absence of
PAbN and reserpine.
Table S2. Seven-day mortality monitoring in a murine
model of peritoneal sepsis. Mice were infected with three
different inocula of Acinetobacter baumannii CipS and CipR.
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